FindTrial
Sign In

Effect of RAS system blockade on the survival rate of transplanted kidney and kidney transplant recipients

Effects of RASBs on the survival rate of transplanted kidney and kidney transplant recipients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058537
Enrollment
Unknown
Registered
2022-04-10
Start date
2022-04-20
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidney transplant

Interventions

Experimental group:RASBs drugs are taken orally
Control group:Oral non-RASBs antihypertensive drugs

Sponsors

The Second Affiliated Hospital of University of South China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients aged > 18 years after kidney transplantation.

Exclusion criteria

Exclusion criteria: 1. Patients with unreversed rejection after kidney transplantation; 2. Patients receiving marginal kidney transplantation; 3. Patients receiving pediatric kidney transplantation; 4. Patients with various recurrence of kidney disease after kidney transplantation; 5. Patients with BK virus-related nephropathy.

Design outcomes

Primary

MeasureTime frame
Urine protein;Serum creatinine;—

Countries

China

Contacts

Public ContactTan Shubo

The Second Affiliated Hospital of University of South China

474268397@qq.com+86 18397438557

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026